Compare Ginkgo Bioworks Holdings Inc (DNA) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Workiva Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.06 (market cap $590.53M), while Workiva Inc trades at $54.51 (market cap $3.01B). The key difference: Workiva Inc is far larger — about 5.1× Ginkgo Bioworks Holdings Inc's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, Workiva Inc nearer its low. Which is the better fit depends on your goals.
| DNA | WK | |
|---|---|---|
Market Cap | $590.53M | $3.01B |
Sector | Health | Technology |
52-Week High | $16.14 | $93.31 |
52-Week Low | $5.48 | $44.31 |
Enterprise Value | $627.78M | $2.94B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Workiva (WK) trades at $54.54, up 4.54% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q1 2026 EPS of $0.77 exceeding expectations. Revenue growth remains solid at $884.57 million for 2025, projected to reach $926 million in 2026. Technical indicators show bullish moving averages while RSI levels suggest potential overbought conditions near-term.
Workiva presents a compelling growth story with 88.9% analyst buy ratings and a $71 consensus price target offering 30% upside. However, elevated valuation multiples (P/E 223.71, EV/EBITDA 71.73) and thin net margins (1.53%) warrant caution. Key risks include competitive pressures in compliance software and execution challenges in maintaining growth momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
